| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
DOPS interacts with various proteins including coagulation factors (factor X, prothrombin) on platelet membranes, as well as with annexins and other phosphatidylserine-binding proteins involved in apoptotic cell clearance (efferocytosis) and immune regulation.
|
|---|---|
| ln Vitro |
DOPS is a key component of blood coagulation. When exposed on activated platelet membranes, DOPS promotes the assembly of intrinsic tenase (factor VIIIa-IXa) and prothrombinase (factor Va-Xa) complexes, accelerating thrombin generation. DOPS-containing liposomes are used to mimic platelet membranes in coagulation studies. Nanovesicles composed of DOPS and saposin C are cytotoxic to SKMEL-28 cells in vitro.
|
| ln Vivo |
In vivo, DOPS-containing nanoparticles have demonstrated therapeutic efficacy. Nanovesicles composed of DOPS and saposin C decrease tumor volume in a squamous cell carcinoma mouse xenograft model. DOPS is used in lipid mixtures with DOPC and DOPE as effective, nontoxic, nonviral DNA vectors for gene delivery applications.
|
| Enzyme Assay |
Systems used to study DOPS include coagulation assays. For in vitro coagulation studies, DOPS is incorporated into liposomes (e.g., DOPC/DOPS mixtures at 20-80 mol%). Recombinant tissue factor and calcium are added to initiate coagulation. Clot formation is measured by turbidity or thrombin generation assays using chromogenic substrates.
|
| Cell Assay |
DOPS is dissolved in chloroform and mixed with DOPC or DOPE at defined molar ratios. Liposomes are prepared by film hydration and extrusion. For cell studies, DOPS liposomes are diluted in buffer and incubated with cells for 2-24 h. Cellular uptake is measured by flow cytometry using fluorescently labeled lipids. Cell viability is assessed by MTT assays. For coagulation studies, platelet-rich plasma is used.
|
| Animal Protocol |
For in vivo gene delivery, DOPS-containing lipoplexes (cationic liposomes formulated with DOPS/DOPE/DNA) are administered intravenously or intratumorally to mice. For cancer therapy, DOPS-SapC nanoparticles are injected intravenously or intratumorally, with tumor volume measured over 2-4 weeks. Biodistribution is assessed by fluorescent labeling or by quantifying encapsulated agents in tissues.
|
| ADME/Pharmacokinetics |
DOPS is an endogenous anionic phospholipid. Following intravenous administration, DOPS-containing liposomes have a circulation half-life of minutes to a few hours. The DOPS headgroup is recognized by phosphatidylserine receptors on macrophages and phagocytes, resulting in rapid clearance from the circulation (primarily via liver and spleen). DOPS is metabolized by phospholipase A2 and other lipid-metabolizing enzymes to free fatty acids, glycerol, and serine, which are used in normal metabolic pathways.
|
| Toxicity/Toxicokinetics |
DOPS is generally well-tolerated. It is an endogenous phospholipid, and natural metabolic pathways exist for its breakdown. In preclinical models, DOPS-containing liposomes are nontoxic at therapeutic doses (up to 50 mg/kg i.v.). High doses may saturate phagocytic clearance, causing transient splenomegaly or hepatomegaly. DOPS exposure on the surface of apoptotic cells facilitates their clearance, preventing autoimmunity; it is non-immunogenic.
|
| References | |
| Additional Infomation |
DOPS-NA (CAS 90693-88-2, C42H₇₇NNaO10P, MW 810.0) has >98% purity and is supplied as a white powder. It is the sodium salt form of DOPS, which improves water dispersibility and solubility. DOPS is used in laboratory research applications, including structural modeling of cellular membranes, drug delivery, apoptosis, coagulation, and gene therapy. No approved clinical uses beyond excipient or research applications have been reported.
|
| Molecular Formula |
C42H77NNAO10P
|
|---|---|
| Molecular Weight |
810.03
|
| Exact Mass |
810.526
|
| CAS # |
90693-88-2
|
| PubChem CID |
23692652
|
| Appearance |
Light yellow to orange solid powder
|
| LogP |
11.762
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
42
|
| Heavy Atom Count |
55
|
| Complexity |
1030
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)([O-])OC[C@@H](C(=O)O)N)OC(=O)CCCCCCC/C=C\CCCCCCCC.[Na+]
|
| InChi Key |
KPHZNDUWYZIXFY-YORIBCANSA-M
|
| InChi Code |
InChI=1S/C42H78NO10P.Na/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(44)50-35-38(36-51-54(48,49)52-37-39(43)42(46)47)53-41(45)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h17-20,38-39H,3-16,21-37,43H2,1-2H3,(H,46,47)(H,48,49);/q;+1/p-1/b19-17-,20-18-;/t38-,39+;/m1./s1
|
| Chemical Name |
sodium;[(2S)-2-amino-2-carboxyethyl] [(2R)-2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl] phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol: 2 mg/mL (2.47 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2345 mL | 6.1726 mL | 12.3452 mL | |
| 5 mM | 0.2469 mL | 1.2345 mL | 2.4690 mL | |
| 10 mM | 0.1235 mL | 0.6173 mL | 1.2345 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
